- Company
- Dt&CRO signs MOU with U.S. company Radyus Research
- by Nho, Byung Chul Mar 27, 2024 06:04am
- On the 25th, Dt&CRO announced that it had signed a memorandum of understanding (MOU) with Radyus Research, a U.S. clinical consulting organization. The MOU is expected to add momentum to the company’s full-cycle consulting service that is provided to domestic pharma and biotech companies that apply for Investigational New Drug (IND) or
- Company
- No news on Phesgo's reimb progress for 7 months
- by Eo, Yun-Ho Mar 27, 2024 06:04am
- The insurance reimbursement process for Phesgo, a drug that was expected to benefit from the preferential drug pricing system, is making little progress. No news has been heard on its progress for 7 months. Roche Korea’s Perjeta (pertuzumab+ trastuzumab), a subcutaneous injectable combination of the company’s Perjeta and Herceptin, pass
- Company
- Adtralza reimb drives biologics competition in atopy market
- by Eo, Yun-Ho Mar 26, 2024 06:30am
- Biopharmaceuticals face competition in the atopic dermatitis sector. According to industry sources, LEO Pharma’s Adtralza (tralokinumab), a treatment for atopic dermatitis with an underlying mechanism of neutralizing interleukin-13 (IL-13), is anticipated to launch with reimbursement starting in May. Adtralza is the second biologic
- Company
- Sam Chun Dang Pharm introduces Eylea biosimilar to Europe
- by Nho, Byung Chul Mar 26, 2024 06:30am
- Sam Chun Dang Pharm announced on the 25th an exclusive distribution agreement for the Eylea biosimilar with nine Western European countries (UK, Belgium, Netherlands, Norway, Portugal, Sweden, Greece, Ireland, and Finland). Under the agreement, Sam Chun Dang Pharm will receive 55% of the partnering company’s net sales, further strength
- Company
- Takeda’s colorectal cancer drug 'Fruzaqla' nears KOR entry
- by Eo, Yun-Ho Mar 26, 2024 06:30am
- New colorectal cancer drug 'Fruzaqla' is likely to receive approval for commercialization in South Korea. According to industry sources on the 11th, Takeda Pharmaceuticals Korea’s Fruzaqla (fruquintinib), designated as Global Innovative products on Fast Track (GIFT) by the Ministry of Food and Drug Safety (MFDS), is under review for app
- Company
- K-bio, R&D global competitiveness will be put to the test
- by Son, Hyung-Min Mar 22, 2024 06:09am
- The Korean pharmaceutical industry will showcase its new candidate products entering late-stage clinical trials or aiming to export technology on platforms, testing their global competitiveness. The spotlight is on these new candidate products, particularly the trending bispecific antibodies and antibody-drug conjugate (ADC), to identify w
- Company
- Lotte Biologics’ sales amount to KRW 228.6 billion
- by Kim, Jin-Gu Mar 22, 2024 06:09am
- Lotte Biologics recorded sales of KRW 228.6 billion last year. As the Syracuse manufacturing plant in the United States went into full-scale production, sales of KRW 83.1 billion in the first half of the year expanded to KRW 145.6 billion in the second half of the year. The analysis indicates that Lotte Biologics’ Contract development
- Company
- Antihistamine sales benefit from end of pandemic and endemic
- by Son, Hyung-Min Mar 22, 2024 06:06am
- Last year, sales of major antihistamines showed a clear recovery, exceeding the level it had made before the pandemic. Sales of antihistamines had plummeted in 2020 and 2021 during the COVID-19 pandemic. The analysis is that the increase in sales is likely due to the rise in allergy patients with the lifted mask mandates and the increase in outd
- Company
- Luxturna prescriptions available for rare retinal disease
- by Eo, Yun-Ho Mar 22, 2024 06:06am
- Prescriptions for the gene therapy ‘Luxturna,’ which targets only a few patients, are becoming available in South Korea. According to industry sources, Novartis Korea’s Luxturna (voretigene neparvovec), a therapy used to treat inherited retinal dystrophy (IRD), has cleared the Drug Committee (DC) of the tertiary general hospitals, in
- Company
- "Envlo shows superior effects in diabetic kidney disease"
- by Son, Hyung-Min Mar 21, 2024 05:52am
- Daewoong Pharmaceutical announced on the 19th that Envlo (ingredient: enavogliflozin), an SGLT-2 class diabetes treatment from the company’s drug discovery, demonstrated superior effects in patients with diabetes compared to dapagliflozin. Based on the clinical results, Envlo has shown superior effects in all four indexes, including ▲
